Payment overview · 2025
General Payments
$804.34
38 reported records · 12 companies
Healthcare provider profile · identity verified
Michael S Basch, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TEMECULA, CA · NPI 1790889350
Verified facts
What the public records show
CMS Open Payments records show Michael S Basch, M.D. received $804.34 in general payments during 2025 across 38 reported records.
Amgen Inc. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $250.90 | 31.2% | 15 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $167.74 | 20.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.90 | 9.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $73.40 | 9.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.34 | 7.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.66 | 6.7% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $25.16 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.61 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.50 | 2.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.30 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.86 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.97 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $804.34 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $250.90 | 15 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $250.90 | 15 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $167.74 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.90 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.90 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $73.40 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.34 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.66 | 3 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 195 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
195 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 419 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 120 |
| Metformin Hcl | Metformin Hcl | 312 | 93 |
| Lisinopril | Lisinopril | 286 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 97 |
| Omeprazole | Omeprazole | 222 | 68 |
| Ozempic | Semaglutide | 195 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 69 |
| Gabapentin | Gabapentin | 184 | 56 |
| Losartan Potassium | Losartan Potassium | 172 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 49 |
| Azithromycin | Azithromycin | 144 | 112 |
| Eliquis | Apixaban | 135 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 50 |
| Furosemide | Furosemide | 129 | 53 |
| Alendronate Sodium | Alendronate Sodium | 119 | 35 |
| Glipizide | Glipizide | 110 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 36 |
| Simvastatin | Simvastatin | 103 | 26 |
| Carvedilol | Carvedilol | 98 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 68 |
| Linzess | Linaclotide | 86 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 28 |
| Potassium Chloride | Potassium Chloride | 77 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 67 |
| Xarelto | Rivaroxaban | 64 | 17 |
| Memantine Hcl | Memantine Hcl | 63 | 23 |
| Trazodone Hcl | Trazodone Hcl | 63 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 19 |
| Lovastatin | Lovastatin | 55 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 22 |
| Famotidine | Famotidine | 50 | 15 |
| Allopurinol | Allopurinol | 49 | 20 |
| Finasteride | Finasteride | 49 | 15 |
| Clonidine Hcl | Clonidine Hcl | 48 | 19 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Meloxicam | Meloxicam | 47 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 31 |
| Methylprednisolone | Methylprednisolone | 45 | 38 |
| Ezetimibe | Ezetimibe | 44 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 16 |
| Farxiga | Dapagliflozin Propanediol | 42 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 11 |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 14 |
| Atenolol | Atenolol | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Naproxen | Naproxen | 27 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 15 |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 14 |
| Nitroglycerin | Nitroglycerin | 25 | 12 |
| Ofloxacin | Ofloxacin | 25 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 24 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Prednisone | Prednisone | 23 | 19 |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | 15 |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 18 |
| Olanzapine | Olanzapine | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 11 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | 12 |
| Lactulose | Lactulose | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Taltz Autoinjector | Ixekizumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $804.34 · 38 records | Amgen Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FREESTYLE LIBRE 3, MOUNJARO, NUZYRA, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, WAKIX, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error